Heverlee, Belgium
Heverlee, Belgium

Time filter

Source Type

Patent
ThromboGenics, Life Sciences Partners and Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Date: 2012-05-02

The present invention provides novel monoclonal antibodies directed to PIGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.


Patent
ThromboGenics | Date: 2012-11-29

A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.


Patent
ThromboGenics | Date: 2013-03-13

The current invention relates to the improvement of trabeculectomy surgery. The improvement more specifically resides in an extended lifetime of the sclera-corneal drainage channel created by trabeculectomy surgery. The improvement is obtained by post-surgical administration of an anti-PlGF antibody or fragment thereof.


The current invention relates to the improvement of trabeculectomy surgery. The improvement more specifically resides in an extended lifetime of the sclera-corneal drainage channel created by trabeculectomy surgery. The improvement is obtained by post-surgical administration of a plasmin or active derivative thereof in the form of topical eye drops alone, by anterior chamber injection alone, or by any combination of these


Patent
ThromboGenics | Date: 2013-04-24

The invention relates to antibodies binding to the PDGF-C antigen and capable of inhibiting binding of PDGF-C to the PDGFR receptor and of inhibiting PDGFR activation by PDGF-C. Applications of such antibodies are also disclosed. These include treatment of cancer.


Patent
ThromboGenics | Date: 2013-03-14

A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.


Patent
ThromboGenics and Peira Bvba | Date: 2012-04-27

This invention concerns a measuring system for the calculation of dimensions, including area and FIG. 4 volume, of objects in various shapes. In particular, it concern miniature 3D measuring equipment that is perfectly suitable for 3D measurements of subcutaneous tumours in mice. The primary objective of this invention then also consists of a measuring system for 3D measurements of objects in various shapes, which includes a handheld device that has at least 1 camera, 1 projector and a measuring chamber. In a more specific implementation, the handheld device will have 2 cameras and a projector and the 3D measurement is based on stereo-vision. It is also the objective of the current invention of a measurement system to ensure that said handheld device also has a processor module, a user interface, power supply and a data communication interface, and exchangeable measuring chambers to give the device the necessary flexibility and autonomy to speed up the measurement procedure, and to significantly improve the reproducibility of the measurement.


Patent
ThromboGenics | Date: 2012-11-30

A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.


The present invention is directed to a method of deriving pluripotent embryonic stem cells from mouse blastocysts or from primordial germ cells from a post-implantation mouse embryo, or of maintaining or growing pluripotent embryonic stem cells from a mouse, or of expanding human hematopoietic stem cells or human hematopoietic precursor cells. The methods include the step of cultivating the stem cells or precursor cells for at least one passage in a culture medium preconditioned by the rabbit fibroblast cell line Rab9 (ATCC catalogue CRL1414) and containing less than 0.1 ng/ml Leukemia Inhibitory Factor (LIF).


Patent
ThromboGenics | Date: 2014-06-27

A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.

Loading ThromboGenics collaborators
Loading ThromboGenics collaborators